Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27853110 | 0.79 | TSHR (0.31) | TSHR | |
| SCHEMBL1500279 | 0.78 | ALDH1A1 (0.41) | TSHR | |
| SCHEMBL753358 | 0.75 | — | — | |
| SCHEMBL17689313 | 0.75 | NLRP3 (0.37) | TSHR | |
| SCHEMBL7695480 | 0.75 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL25025480 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL1096715 | 0.74 | TSHR (0.30) | TSHR | |
| SCHEMBL9549066 | 0.74 | TSHR (0.30) | TSHR | |
| SCHEMBL14960474 | 0.73 | TSHR (0.35) | TSHR | |
| SCHEMBL28980826 | 0.73 | TSHR (0.36) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042843-A1 | METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS | Temple Therapeutics BV (NL) | 2026-02-12 | — | — | US | disclosed |
| US-20260022399-A1 | AAV-BASED TREATMENT FOR ALAGILLE SYNDROME | BAYLOR COLLEGE OF MEDICINE (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4651881-A1 | AAV-BASED TREATMENT FOR ALAGILLE SYNDROME | Baylor College of Medicine (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4637717-A1 | LIPID PARTICLE COMPOSITIONS AND METHODS OF USE THEREOF | Pfizer Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250319117-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250283062-A1 | SYSTEMS AND METHODS FOR MODULATING RNA | THE UNIVERSITY OF CHICAGO (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250235524-A1 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | PFIZER INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250223646-A1 | METHODS FOR DETECTING AND TREATING CEREBRAL CAVERNOUS MALFORMATION | THE UNIVERSITY OF CHICAGO (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025128661-A1 | COMPOSITIONS AND METHODS FOR TARGETING ASTROCYTES TO TREAT NEUROLOGICAL DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250177514-A1 | CORONAVIRUS ANTIGEN VARIANTS | PFIZER INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-1995018136-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS AND SOLID PHASE SYNTHESIS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5386023-A | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling | ISIS PHARMACEUTICALS (US) | 1995-01-31 | — | — | US | disclosed |
| US-5378825-A | Backbone modified oligonucleotide analogs | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994022893-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022883-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDES AND THEIR PREPARATION | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022454-A1 | OLIGONUCLEOSIDE LINKAGES CONTAINING ADJACENT OXYGEN AND NITROGEN ATOMS | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0586520-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586570-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020822-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020823-A1 | BACKBONE MODIFIED OLIGONUCLEOTIDE ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235524-A1 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | SNRPF, LNPEP, RNASEH1 | TSHR 1570/4885 |
| US-20260042843-A1 | METHODS FOR TREATING ENDOMETRIAL AND OVARIAN HYPERPROLIFERATIVE DISORDERS | MPO, ITGB2, ITGB1 | TSHR 1468/4885 |
| US-20250319117-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROSIS | ITGB3, ITGB2, ITGA2 | TSHR 2828/4885 |
| US-20260022399-A1 | AAV-BASED TREATMENT FOR ALAGILLE SYNDROME | NOTCH4, NOTCH2, NOTCH1 | TSHR 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.